A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Nivolumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 548
- Sponsors Bristol-Myers Squibb
- 19 Jul 2017 Planned End Date changed from 9 Nov 2020 to 8 Jan 2023.
- 19 Jul 2017 Planned primary completion date changed from 12 Jun 2019 to 6 Nov 2021.
- 26 Jun 2017 Planned number of patients changed from 320 to 693.